Facebook icon Twitter icon Forward icon

Drug tariff approval prompts FreeStyle Libre prescriptions rise

The number of prescriptions written for the FreeStyle Libre rose by 285 per cent in just one month following its NHS availability last year, according to new data.

The figures were calculated by the website Open Prescribing, run by the EBM DataLab at the University of Oxford. To read more, click here

Pharmacist-led review improves key care processes uptake

The proportion of people with type 2 diabetes who received all the annual nine key care processes increased from 46 per cent to 58 per cent in one year following a pharmacist-led review.

Pharmacists reviewed 5,910 people with the condition from 13 GP surgeries in the NHS Slough Clinical Commissioning Group (CCG) area. To read more, click here

TREND-UK announces annual conference dates

The forthcoming dates for TREND-UK’s National Annual Conference have been announced.

Once again, the event will be held in two different UK locations to make access for attendees easier. To read more, click here

Type 1 collaborative webinar announced

Diabetes consultants with an interest in type 1 diabetes have been invited to join a "must see" webinar about flash glucose monitoring and continuous glucose monitoring. 

The online one-hour event, set to take place on Tuesday, February 27 from 5pm, has been set up by the Association of British Clinical Diabetologists (ABCD). To read more, click here

NHS England praises regional diabetes services

Diabetes care across Suffolk and north east Essex has been rated “outstanding” by NHS England.

Inspectors praised local services for providing high-quality care for the 48,000 people living in the areas. To read more, click here

Study highlights positive cardiovascular and renal outcomes of SGLT2 Inhibitors in type 2 diabetes

SGLT2 inhibitors showed “remarkable” cardiovascular and renal‐protective effects and “good” long‐term non-cardiovascular safety with sustained efficacy in type 2 diabetes, a summary of available evidence has suggested.

A systemic review and meta-analysis with trial sequential analysis was carried out into the cardiovascular and long‐term, non-cardiovascular safety and efficacy of SGLT2 inhibitors. To read more, click here